US2020102564A1PendingUtilityA1
Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
Est. expiryDec 7, 2032(~6.4 yrs left)· nominal 20-yr term from priority
B82Y 5/00A61K 47/543A61K 49/0423A61K 47/549C12N 2320/30C12N 15/1135
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.
Claims
exact text as granted — not AI-modified1 . A method for alleviating at least one symptom associated with myeloproliferative neoplasms or myelodysplastic syndrome in an individual in need thereof, the method comprising:
administering a clinically effective amount of a telomerase inhibitor to the individual, wherein administration of the telomerase inhibitor alleviates at least one symptom associated with myeloproliferative neoplasms or myelodysplastic syndrome.
2 .- 41 . (canceled)Join the waitlist — get patent alerts
Track US2020102564A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.